1. Anker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler-Klein J, A de Boer R et al. Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018. ESC Heart Fail. 2018;5(6):1083–1091.
2. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026
3. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi:10.1002/ejhf.1920
4. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966–1983. doi:10.1002/ejhf.2017
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14. doi:10.1002/1097-0142(197308)32:23.0.co;2-2
6. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.023
7. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–1729. doi:10.1093/eurheartj/ehaa006
8. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi:10.1136/heartjnl-2017-312103
9. Renu K, Abilash V G, Tirupathi Pichiah PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy — an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.043
10. Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Current Problems in Cardiology. 2021;100909. doi:10.1016/j.cpcardiol.2021.100909
11. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–1129. doi:10.1152/physrev.00006.2004
12. Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6(4):1675–1699. doi:10.1002/cphy.c150056
